Nothing Special   »   [go: up one dir, main page]

Prahallad et al., 2012 - Google Patents

Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR

Prahallad et al., 2012

View PDF
Document ID
15384732763035088885
Author
Prahallad A
Sun C
Huang S
Di Nicolantonio F
Salazar R
Zecchin D
Beijersbergen R
Bardelli A
Bernards R
Publication year
Publication venue
Nature

External Links

Snippet

Inhibition of the BRAF (V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF (V600E) oncogenic lesion have poor prognosis and …
Continue reading at iris.unito.it (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Similar Documents

Publication Publication Date Title
Prahallad et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR
Goodwin et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Santana-Codina et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Furnari et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Sen et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer
Yan et al. A dynamic N 6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors
Hata et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Taniguchi et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Chen et al. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition
Lee et al. Targeting glutamine metabolism slows soft tissue sarcoma growth
Zhang et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Rabé et al. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma
Abraham et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Juvekar et al. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Zuber et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Emery et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition
Weisberg et al. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
Sullivan et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Hong et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
Chu et al. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells
Smida et al. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Stewart et al. KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine
Kobayashi et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Ghezzi et al. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells
Hata et al. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers